Comparison of prognostic models for patients with early-stage diffuse large B-cell lymphoma]

Weiping Liu,Xiaopei Wang,Chen Zhang,Yan Xie,Ningjing Lin,Meifeng Tu,Lingyan Ping,Zhitao Ying,Lijuan Deng,Huiying Huang,Meng Wu,Yingli Sun,Tingting Du,Xin Leng,Ning Ding,Wen Zheng,Yuqin Song,Jun Zhu

DOI: https://doi.org/10.3760/cma.j.issn.0253-2727.2016.04.002

2016-01-01

Abstract:To compare the prognostic value of different models in patients with early-stage diffuse large B-cell lymphoma (DLBCL).Early-stage DLBCL patients diagnosed from January 2000 to December 2012 were analyzed retrospectively. All patients received with at least 2 cycles of immunochemotherapy R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) with or without radiotherapy. The prognostic value of international prognostic index (IPI) , revised IPI (R-IPI) and enhanced IPI (NCCN-IPI) was compared.Ninety-seven cases of early-stage DLBCL were included in the study. The median age was 58 years (15-88 years) with a median follow-up of 34.7 months (range 7.3-77.4 months). The expected 5-year overall survival (OS) for entire group was 82%. There was no patient in the high risk group according to IPI or NCCN-IPI. According to IPI, the 5-year OS in the low, low intermediate, high intermediate risk groups were 95%, 38% and 60%, respectively. According to R-IPI, the 5-year OS in the very good, good, and poor risk groups were 93%, 75% and 60%, respectively. According to NCCN-IPI, the 5-year OS in the low, low intermediate, high intermediate risk groups were 92%, 85% and 29%, respectively.NCCN-IPI would be of an ideal prognostic model for early-stage DLBCL patients.